FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
34 letters match. Newest first.
-
BiologicsNexCell Scientific Inc
NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.
High risk -
BiologicsBlue Horizon International, LLC
FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.
High risk -
DrugsCenter For Immunology Science, LLC
FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.
High risk -
DrugsPamela K. Den Besten, DDS, MS
FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.
High risk -
DrugsAmerican Behavioral Research Institute, LLC
FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.
High risk -
BiologicsSupreme Rejuvenation, LLC
FDA warned Supreme Rejuvenation that its exosome products are unapproved new drugs and unlicensed biological products.
High risk -
BiologicsMG Infusions
FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.
High risk -
DrugsRichard W. Foltin, Ph.D.
FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.
High risk -
BiologicsMother Stem Institute, Corp.
FDA warns Mother Stem Institute over unapproved fat-derived SVF 'stem cell' biologic marketed for serious diseases.
High risk -
BiologicsBerkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.
FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.
High risk -
BiologicsNeobiosis, LLC
FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.
High risk -
BiologicsAkan Biosciences, Inc.
FDA warned Akan Biosciences over unapproved Ayama injectable and donor-screening failures.
High risk -
BiologicsHuman Microbes
FDA warned Human Microbes that selling fecal microbiota for transplantation as an unapproved drug and unlicensed biologic lacks required BLA or IND.
High risk -
BiologicsKimera Labs, Inc.
FDA warns Kimera Labs over unapproved exosome and amniotic fluid products and serious sterile manufacturing failures.
High risk -
BiologicsAbbott Laboratories
FDA warns Abbott that Similac Probiotic Tri-Blend for preterm infants is an unapproved drug and adulterated supplement.
High risk -
BiologicsInfinant Health, Inc formerly Evolve Biosystems Inc.
FDA says Infinant Health's Evivo with MCT Oil probiotic is an unapproved biologic drug and unsafe food additive for preterm infants.
High risk -
BiologicsSignature Biologics, LLC
FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.
High risk -
BiologicsStratus Biosystems, LLC dba CellGenuity Regenerative Science
FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.
High risk -
BiologicsRow1 Inc. dba Regenative Labs
FDA warned Regenative Labs that its umbilical cord products are unlicensed drugs, made under serious sterility and manufacturing failures.
High risk -
DrugsTyrone L. McCall, M.D./Cornea Associates of Texas
FDA warns Dallas eye practice Cornea Associates for running a 69-subject drug study without an IND.
High risk -
Drugs"David M. Lubeck, M.D./Arbor Centers for EyeCare
FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.
High risk -
BiologicsInvitrx Therapeutics, Inc.
Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.
High risk -
BiologicsBioLab Sciences, Inc.
FDA warned BioLab Sciences that its injected amniotic fluid and skin products were unapproved biologics with serious manufacturing violations.
High risk -
BiologicsVitti Labs, LLC
FDA warns Vitti Labs over unapproved umbilical cord and amniotic membrane products and sterile manufacturing failures.
High risk -
DrugsDaniel Fred Goodman, M.D./Goodman Eye Center
FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.
High risk -
BiologicsRe-Gen Active Lab, Inc.
FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.
High risk -
DrugsCytoDyn, Inc.
FDA warns CytoDyn over video promoting unapproved leronlimab as safe and effective for COVID-19.
High risk -
BiologicsSurgenex LLC
FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.
High risk -
DrugsLauren R. Klein, MD, M.S.
FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.
High risk -
DrugsJon B. Cole, MD
FDA warns Dr. Jon B. Cole he ran two pre-hospital drug studies without required INDs, adding risks for pregnant women, children, and intoxicated patients.
High risk -
DrugsRAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.
FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.
High risk -
DrugsKaleido Biosciences, Inc.
Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.
High risk -
BiologicsDavati Medical Supply LLC
FDA warned Davati Medical Supply for selling unapproved, unlicensed FLUZALP Quadrivalent influenza vaccine online in the U.S.
High risk -
DrugsKDunn and Associates, P.A. dba HealthQuilt
Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.
High risk